PCP
FATE icon

Proficio Capital Partners’s Fate Therapeutics FATE Stock Holding History

Proficio Capital Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.9K Buy
+26,252
New +$48.6K ﹤0.01% 681
2019
Q3 		– Sell
-105
Closed -$2K – 609
2019
Q2 		$2K Hold
105
– – ﹤0.01% 1532
2019
Q1 		$2K Buy
+105
New +$1.66K ﹤0.01% 1354

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Proficio Capital Partners's FATE Position: Q2 2026 in Review

Proficio Capital Partners opened a new position in Fate Therapeutics (FATE) in Q2 2026: 26,252 shares worth $70.9K. The stake represents ﹤0.01% of the portfolio and ranks #681 among its holdings. This is a return to the name: Proficio Capital Partners previously reported a position in FATE as recently as Q2 2019.

Proficio Capital Partners first reported a position in FATE in Q1 2019 and has held it in 3 quarters since. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Proficio Capital Partners held 26,252 shares of Fate Therapeutics worth $70.9K as of Q2 2026.
  • Fate Therapeutics was a new Proficio Capital Partners position in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of Proficio Capital Partners's portfolio in Q2 2026, its #681 holding.
  • Proficio Capital Partners first reported a position in Fate Therapeutics in Q1 2019 and has held it in 3 quarters since.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Proficio Capital Partners's 13F filing for Q2 2026, filed 17 Aug 2026.